DELOS Desarrollo Local Sostenible
June 3, 2026
Ana Lara Mendonça, Déborah Rezende, Gabriela Alves et al.
Ibogaine, an indole alkaloid from Tabernanthe iboga, may reduce withdrawal symptoms, craving, and relapse in substance use disorders. A literature review of publications from PubMed, Scopus, Medline, Google Scholar, and SciELO shows ibogaine acts via multiple systems: glutamatergic, opioid, serotonergic, and nicotinic, with possible effects on neuroplasticity and reward circuits. Observational clinical studies indicate reductions in withdrawal and craving, and recent research describes improved psychiatric and cognitive outcomes in controlled settings. However, safety remains a major limitation, particularly the risk of corrected QT interval prolongation, ventricular arrhythmias, and serious cardiac events. The therapeutic potential is relevant but depends on randomized controlled trials, rigorous monitoring, clear regulatory criteria, and hospital protocols to reduce patient risks.
DELOS Desarrollo Local Sostenible
December 11, 2025
Pedro Rodrigues, Weliton Rodrigues Dos Santos Júnior, Ivan de Sousa Araújo et al.
A systematic review and network meta-analysis of 149 randomized controlled trials compared psilocybin, ketamine, and several common antidepressants (escitalopram, bupropion, paroxetine, fluoxetine, sertraline, venlafaxine) against placebo for major depressive disorder. All antidepressants were more effective than placebo, but psilocybin and ketamine achieved the lowest depressive symptom scores and reduced suicidal ideation. For acceptability (measured by dropout rates), placebo outperformed all drugs; however, among the medications, psilocybin had the highest combined ranking for efficacy and acceptability, followed closely by ketamine. The authors suggest these two agents may aid physicians in therapeutic decision-making, including for treatment-refractory depression.
DELOS Desarrollo Local Sostenible
November 12, 2025
Maria Eduarda Mesquita Gonsalves, Beatriz Moreira Brazil, Maurício Cupello Peixoto
Post-traumatic stress disorder (PTSD) is a mental condition that can arise after traumatic experiences, affecting individuals' quality of life. Conventional treatment involves psychotherapy and pharmacotherapy, but does not always yield satisfactory results. In this context, MDMA-assisted psychotherapy has emerged as a promising alternative. This integrative review analyzed the efficacy and safety of MDMA as a therapeutic facilitator for PTSD. Nine clinical trials published between 2019 and 2024 were included. Results showed significant symptom reduction, greater therapeutic adherence, prolonged effects, and diagnostic remission in some patients.